Placebo to match idelalisib

DRUG2 trials

Conditions

Chronic Lymphocytic Leukemia

Phase 3

A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

CompletedNCT01539512

Gilead SciencesChronic Lymphocytic Leukemia

Start: 2012-04-30End: 2014-04-30Updated: 2019-05-14

Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )

CompletedNCT01569295

Gilead SciencesChronic Lymphocytic Leukemia

Start: 2012-06-15End: 2019-06-10Updated: 2020-03-10

Leukemia & lymphoma/Leukemia and lymphoma2020-12-102 citations

Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials

British Journal of Haematology2020-06-2926 citations

Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial.

2019-11-159 citations

PS1153 IMPACT OF COMORBIDITIES ON OUTCOMES OF THERAPY WITH IDELALISIB (IDELA), A PHOSPHOINOTISIDE‐3 KINASE‐DELTA INHIBITOR, IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

HemaSphere2019-06-01

Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy

Blood2018-11-29

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.

2017-01-28198 citations

Whole-Exome Sequencing Revealed No Recurrent Mutations within the PI3K Pathway in Relapsed Chronic Lymphocytic Leukemia Patients Progressing Under Idelalisib Treatment

Blood2016-12-0225 citations

Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL

Blood2016-12-027 citations

Temporal Profiles of Lymphocyte Subsets and the Correlation with Infectious Events in Idelalisib-Treated Patients

Blood2016-12-023 citations

An evaluation of the chronic lymphocytic leukemia (CLL) international prognostic index as a prognostic tool in patients with relapsed/refractory CLL in idelalisib phase 3 randomized studies.

Journal of Clinical Oncology2016-05-203 citations

Outcomes of patients with relapsed and refractory chronic lymphocytic leukemia (CLL) who discontinue idelalisib treatment.

Journal of Clinical Oncology2016-05-202 citations

Management of transaminase elevations in patients receiving idelalisib.

Journal of Clinical Oncology2016-05-202 citations

Results of a randomized, double-blind placebo-controlled phase 3 study evaluating idelalisib in combination with bendamustine and rituximab in patients with relapsed/refractory CLL and adverse prognostic features.

Journal of Clinical Oncology2016-05-201 citations

Patterns of hepatitis B reactivation and liver test abnormalities in patients with chronic lymphocytic leukemia (CLL) treated with idelalisib plus an anti-CD20 antibody.

Journal of Clinical Oncology2016-05-201 citations

Idelalisib Plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study

Blood2015-12-0334 citations

Idelalisib Treatment Is Associated with Improved Cytopenias in Patients with Relapsed/Refractory iNHL and CLL

Blood2015-12-031 citations

Patterns of Lymphocytosis in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Treated with Idelalisib

Blood2015-12-03

Outcomes of anticoagulant (AC) or antiplatelet (AP) use in patients (pts) with chronic lymphocytic leukemia (CLL) or indolent non-Hodgkin’s lymphoma (iNHL) in idelalisib (IDELA) trials.

Journal of Clinical Oncology2015-05-203 citations

Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL.

Journal of Clinical Oncology2014-05-2012 citations

Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial.

Journal of Clinical Oncology2014-05-2011 citations

4 more papers not shown

Placebo to match idelalisib

Sponsors

Conditions

Phase 3

Related Papers